INTRODUCTION
Patients with severe hemophilia A complicated with high titers of antibodies against Factor VIII:CAg represent a serious therapeutic problem. Recently, the use concentrates of the unactivated and activated prothrombin-complex have met with limited success in some cases (1) (2) (3) (4) (5) , while in others, evidence of disseminated intravascular coagulation or thromboembolic complications were observed (6) (7) (8) . The putative hemostatic agent(s) in these preparations has never been identified, although Factor VIIa has been suggested as one possibility (9) . Factor Vlla has an absolute requirement for tissue factor for expression of its proteolytic activity. In addition, Factor VIIa is not inhibited to any significant extent by antithrombin III in the absence of heparin (10) . Thus, it is possible that upon administration, Factor VIIa may find its way Received for publication 16 November 1982 and in revised form 15 February 1983. unabated to the site of trauma, complex specifically with tissue factor at the site, and rapidly initiate the formation of thrombin by the extrinsic pathway. This mechanism would "by-pass" the intrinsic pathway, which requires normal levels of Factor Factor XII, Factor XI, Factor V, Owren's P + P (prothrombin plus Factor VII plus Factor X), fibrinogen, and fibrinogen/fibrin degradation products were assayed as previously described (11) . Prothrombin time, thrombin time, and reptilase time were performed as described (11) . Factor VIII coagulant activity (VIII:C) and Factor VIII-related antigen (VIII:RAg) were assayed according to Nilsson (12) and Holmberg and Nilsson (13) , respectively. Antithrombin III and a2-antiplasmin were assayed by electroimmunoassay (14) as well as by amidolytic assay using S-2238 and S-2251, respectively. Factor X and prothrombin were assayed by one-stage assays according to Bachmann et al. (15) and Hjort et al. (16) , respectively. Factor IX coagulant activity (IX:C) was assayed by a one-stage assay (12) and Factor IX antigen (IX:Ag) was assayed by the immunoradiometric assay as described by Holmberg et al. (17) . Factor VII was assayed by a one-stage assay using hereditary Factor VII-deficient human plasma and human thromboplastin (10) . One unit of Factor VII activity is arbitrarily defined as that amount of activity present in 1 ml of normal, pooled human plasma. The inhibitory activity of the plasma was expressed in Bethesda units (BU)' (18) .
Preparation of human Factor VIIa
Factor VII was purified from human citrated fresh-frozen plasma through the DEAE-Sepharose step essentially as described by Broze and Majerus (10) . Fractions from the DEAE-Sepharose containing Factor VII activity were pooled, concentrated to -30 ml by ultrafiltration, and dialyzed overnight against 0.05 M Tris-HCl (pH 8.0)/0.15 M NaCl/10 mM benzamidine. The retentate was applied to a QAE-Sephadex A-50 column (1.6 X 35 cm) previously equilibrated at 4°C with 0.05 M Tris-HCl (pH 8.0)/0.15 M NaCl/l mM benzamidine. Factor VII was eluted from the column with a linear gradient of CaC12 consisting of 150 ml of equilibrating buffer and 150 ml of equilibrating buffer containing 10 mM CaCl2. The fractions containing Factor VII were combined, made 10 mM in EDTA, and concentrated to 10 ml by ultrafiltration. The concentrate was dialyzed overnight at 4°C against 25 mM Tris-HCI (pH 8.0)/25 mM glycine/ 20 mM benzamidine/5 mM EDTA, and subsequently subjected to preparative electrophoresis as described (19) . Fractions were assayed immediately after elution from the preparative electrophoresis column, and those containing Factor VII activity pooled, and concentrated to -0.5 mg/ml by ultrafiltration. Factor VII isolated by this procedure appeared as a single band by SDS-polyacrylamide gel electrophoresis in the presence or absence of reducing agent. The molecular weight noted by this technique was 50,000 and the specific clotting activity was 2 U/jig. Single-chain Factor VII was converted to the two-chain Factor VIIa by limited proteolysis using human Factor XIIa at an enzyme-to-substrate weight ratio of 1:100. Two-chain human a-Factor XIIa was generously provided by Dr. Kazuo Fujikawa, University of Washington. The Factor XII was isolated from human plasma as described (20) , and converted to two-chain Factor XIIa by human kallikrein in the presence of dextran sulfate (21) 20-25% of the Factor VIIa activity was lost during the sterilization-filtration process. Portions of the sterilized preparations were analyzed for pyrogens (the National Bacterial Laboratory, Stockholm, Sweden) and for HbsAg using the Ausria II assay (Abbott Laboratories, North Chicago, IL). The sterilized Factor VIla was stored at -80°C in 0.5-ml aliquots (-10,000 U per vial) before use. Before infusion, each preparation was diluted with sterile saline to the concentration desired.
Protocol for the infusion of human Factor VIIa
These studies were conducted with the approval of the Human Subjects Committee of the University of Lund, Malmo, Sweden, and followed guidelines established by the Declaration of Helsinki. _I --20,000 ---14A400 (20, 000) , and a-lactalbumin (14, 400) . Electrophoresis was carried out in 10% polyacrylamide gels as previously described (19) .
Factor VIla preparations was examined in healthy dogs by essentially the same protocol described for the analysis of prothrombin complex concentrates (11) . No attempt was made to remove the trace amounts of Factor XIIa present in the Factor VIIa preparations. Accordingly, these studies examined the thrombotic potential of Factor XIIa as well as Factor VIla. Each preparation of Factor VIla was given to a mongrel (16) (17) kg) in a dose of 50-100 U Factor VII/ kg body wt (BW). The concentrate was given intravenously in 3 ml of sterile saline without anesthesia. The sampling was performed by intermittent venous puncture before the injection, and 15 min, 1, 4, and 24 h after injection. Each time, 30 ml of blood was withdrawn and anticoagulated with 0.038% sodium citrate. After infusion of Factor VIla, absolutely no change in the coagulation or fibrinolytic profile was observed in the dog plasma except the expected rise in plasma Factor VII (Table I) . Furthermore, the dogs did not exhibit any untoward side effects during or after the injection of Factor VIla.
Case reports Case 1. A 13-yr-old male with severe hemophilia A was admitted to the hospital with bleeding in the left gastrocnemius muscle. The circumference of the left leg just below the knee was 33.5 cm as compared with 30 cm for the right (18) 17 (18) 17 (18) 17 (18) 18 (18) 18 (18) 18 (18) 17 (18) 18 (18) VIII 
RESULTS
Infusion of purified human Factor Vlla into two patients with hemophilia A with antibodies against Factor VIII:C produced no immediate adverse effects such as chills, nausea, flush, or urticaria. Furthermore, no evidence of consumption coagulopathy, disseminated intravascular coagulation, or increase in factor VIII:C antibody titer were observed in either patient throughout the treatment. Table II contains the coagulation pattern of patient 1 before and after the administration of Factor VIIa. The coagulation pattern of patient 2 was virtually identical (data not shown). No hepatitis has occurred thus far in either patient (one patient followed for 1.5 yr and the other for 3 mo) following the last infusion of Factor Vlla. The postinfusion recovery of Factor VIIa (measured 15 min after infusion) ranged from 38 to 45%, assuming no extravascular equilibration and 40 ml blood/kg BW. Depending on the injection dose, the plasma Factor VII activity of each patient returned to preinjection levels in -5-8 h. A shortening of the prothrombin time in the patient's plasma by an average of 2 s occurred invariably on each administration. The effect of Factor VIIa on the muscle bleeding (patient 1) and the knee joint bleeding (patient 2) was evaluated by the decrease in leg circumference 24 h after the administration. As for the muscle bleeding, a softening of the tissue and a decreased tenderness were evident within 2 h after the administration of Factor VIIa. A subjective disappearance of the discomfort associated with the knee joint was also noted within a few hours after infusion of Factor VIIa.
Perhaps the most dramatic evidence of the hemostatic effectiveness of Factor Vlla was associated with Factor VIla in Hemophiliacs with Inhibitors the mucocutaneous bleedings following the loss of a primary tooth in patient 2. In this episode, the patient had spontaneously lost a primary molar and developed a loose clot in the cavity. This clot was typical for patients with hemophilia in that it was huge, of fragile consistency, and hanging from the back of the throat. Signs of an ongoing diffuse bleeding around this clot were also fully visible upon admission. Following extraction of two additional molars, and the administration of Factor VIla and tranexamic acid, a small clot of a normal appearance could clearly be seen in the cavities and no diffuse bleeding ever occurred later than 30 min after the extraction.
DISCUSSION
A number of investigators have reported on the successful use of both ordinary prothrombin complex concentrates (1, 2) and socalled activated prothrombin complex concentrates (3) (4) (5) in the treatment of hemophilia A patients complicated with inhibitors. However, such concentrates also have been reported to be thrombogenic (6) (7) (8) . Activated prothrombin complex concentrates contain Factors IX, X, VII, and prothrombin in both activated and zymogen forms. Thus far, no consensus has been reached on which of these factors possess Factor VIII bypassing activity, and which factor (or factors) is responsible for the thrombogenic properties.
Factor VIla converts Factor X to Factor Xa in the presence of tissue factor and calcium ions (22) , thus establishing a Factor VIII bypassing mechanism for thrombin formation. As 
